
More than two dozen attorneys general push Medicare to cover new Alzheimer's treatments
Twenty-six attorneys general on both sides of the aisle called on Medicare on Monday to cover antibody-based Alzheimer’s treatments like Eisai and Biogen’s Leqembi (lecanemab) without restrictions and to reverse a controversial policy that limits coverage to patients in clinical trials.
The letter, led by Oklahoma Attorney General Gentner Drummond and Minnesota’s Keith Ellison, asked CMS for “full and unrestricted coverage” of FDA-approved monoclonal antibodies directed against amyloid for Alzheimer’s treatment. The push for change comes from 23 states, the District of Columbia and two US territories too.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.